EU Regulatory News Round Up: NSAIDs During Pregnancy, Estragole Excipients, ePIs
Executive Summary
CMDh receives applications to change how NSAIDs are recommended for use during pregnancy; HMPC warns against use of estragole-containing excipients in herbals; EMA adopts new EU common standard for electronic product information on medicines marketed within the region.
You may also be interested in...
EU Bitter Fennel Oil Monograph May Be Withdrawn Due To Estragole Safety Concerns
The European Medicines Agency’s Committee on Herbal Medicinal Products (HMPC) says the EU herbal monograph for bitter fennel oil “cannot be supported anymore” because of new data on the genotoxicity and carcinogenicity of estragole.
UK Consumers Want Greener Manufacturing, Recyclable Packaging And Better Information
Commitments to environmentally sustainable production processes and recyclable packaging for OTC products are increasingly important to UK consumers, according to a recent PAGB survey. Consumers would also like more information about how products should be recycled and are open to the idea of electronic product information.
Haleon, Teva And PAGB Join UK Sustainable Medicines Partnership
Haleon, Teva and UK consumer healthcare industry association, PAGB, are among 42 members of the Sustainable Medicines Partnership, which “aims to build science-based, scalable, sustainable solutions to help reduce the waste of medicines and the waste from medicines.”